cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
-
Editorial Address
-
Location
,
INDONESIA
The Indonesian Biomedical Journal
Published by The Prodia Education and Research Institute
ISSN : -     EISSN : -     DOI : -
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Public Health
Arjuna Subject : -
Articles 601 Documents
 8   9   10   11   12 
Mesenchymal Stem Cells Manage Endogenous Tissue Regeneration Anna Meiliana; Nurrani Mustika Dewi; Andi Wijaya
The Indonesian Biomedical Journal Vol 8, No 2 (2016)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v8i2.211

Abstract

BACKGROUND: Current findings set a new understanding that every adult tissue has its own intrinsic progenitor or stem cell, give a potency for their innate turnover dynamics. This broke the old assumption that adult tissues cannot regenerate themselves. Localized tissue regeneration was regulatory oversight by a separate class of local cells originating as perivascular cells, suggested a profound influence on using specific cells for cell therapies as a health care delivery tool set.CONTENT: The mesenchymal stem cell (MSC) could be mobilized from the marrow or other depots or can be culture-expanded MSCs which are delivered to the damage site either by direct or systemic injection. MSCs act paracrine and autocrine by inducing a variety of cytokines and growth factors which suppress local immune system, inhibit fibrosis (scar formation) and apoptosis, enhanceangiogenesis, and stimulate mitosis and differentiation of tissue, intrinsic reparative or stem cells. These referred a trophic effects, different from the direct differentiation of MSCs into repair tissue. Thus, MSC suggested as a multidrug delivery vehicles in response of injury. In this regard, the trophic effects of MSCs may have profound clinical use.SUMMARY: Managing the body’s natural repair and regeneration capacities is the new frontier for modern medicine and the basis for the science of cell therapies. Study of MSCs become one avenue that being pursued to explore the endogenous tissue regeneration management, so that people have a great expectation to solve many severe diseases.KEYWORDS: mesenchymal stromal/stem cell, paracrine or autocrine activities, trophic mediator, inflammation, wound healing
Endothelial Progenitor Cells in Diabetic Vasculopathy Anna Meiliana; Andi Wijaya
The Indonesian Biomedical Journal Vol 1, No 2 (2009)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v1i2.89

Abstract

BACKGROUND: The discovery of endothelial progenitor cell (EPC) a decade ago by Asahara, et al has refuted the previous belief that vasculogenesis only occurs during embryogenesis. The reduced circulating concentration of EPCs is a surrogate marker of endothelial function and has been implicated in the pathogenesis of many vascular diseases.CONTENT: Diabetes is linked to impaired vascular function, including alterations in both endothelial cells and EPCs. A number of studies have shown that individuals with diabetes have decreased level of circulating EPCs and that the severity of disease is inversely proportional to EPC levels. In vitro, hyperglycemia increases the rate of EPC senescence and the angiogenic function of EPCs from patients with either type 1 or type 2 diabetes is impaired such that they are poorly proliferative and fail to incorporate into forming vessel-like structures. Given the comprehensive role of EPC alterations in diabetes complications, modulation of the levels and/or function of EPCs may be considered a potential therapeutic strategy.SUMMARY: The available data demonstrating that decrease or dysfunction of EPCs may have a prominent role in the pathogenesis of all diabetes complications. Further approaches, such as EPC administration, may represent novel treatments for diabetic vasculopathy in the future. To date, many barriers remain to such a therapeutic approach. Firstly, there is no specific marker for EPC at present. Secondly, techniques of EPC isolation are not standardized, preventing direct comparison between various studies. The long-term effects of transplanted EPCs are currently unknown.
The Relationship of Proinflammatory and Antiinflammatory Adipokines in the Development of Metabolic Syndrome in Centrally Obese Men Anna Meiliana; Andi Wijaya; Suryani As'ad
The Indonesian Biomedical Journal Vol 2, No 3 (2010)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v2i3.125

Abstract

BACKGROUND: The increased prevalence of obesity worldwide is correlated with increasing prevalence of metabolic syndrome. Studies of adipose tissue have been improved from an inert energy storage to a metabolic active endocrine organ. Adipokines secreted by this tissue play a role in maintaining metabolic homeostasis. The large mass of visceral fat tissue causing the imbalance of these adipokines leading to metabolic abnormality known as the metabolic syndrome (MetS). This study was performed to understand relationship of proinflammatory adipokines (resistin, TNF-α, RBP4 and visfatin) and anti-inflammatory adipokines (adiponectin and vaspin) in the development of MetS.METHODS: This was a cross-sectional study using 122 central obesity men with waist circumference >90 cm, age from 30–60 years old. Proinflammatory adipokines (resistin, TNF-α, RBP4 and visfatin) and anti-inflammatory adipokines (adiponectin and vaspin) was measured by ELISA method.RESULTS: The crosstab study showed that subjects who have >2 high proinflammatory adipokines (17.3%) has higher MetS prevalence (OR = 1.16; p = 0.72) compare to subjects with <2 high proinflammatory adipokines (14.8%), subjects with low anti-inflammatory adipokines profile (18.9%) has higher prevalence of MetS (OR=1.38; p=0.22) compare to subjects with high anti-inflammatory adipokines (13.7%) and the prevalence of MetS became 1.49 times higher (p=0.24) when we combine the high RBP4 and low adiponectin profile (21.1%) compare to subjects with low RBP4 and high adiponectin (14%).CONCLUSIONS: This study showed that each adipokine was not strong enough to induce MetS, so the interaction between proinflammatory and antiinflammatory adipokines were needed to induce a systemic metabolic abnormality. Thus, the adipokines equilibrium was important to prevent MetS especially in centrally obese subjects.KEYWORDS: obesity, metabolic syndrome, adipokines, resistin, TNF-α, RBP4, visfatin, adiponectin, vaspin
The Dynamic Roles of Visfatin and Obestatin Serum Concentration in Pancreatic Beta Cells Dysfunction (HOMA-beta) and Insulin Resistance (HOMA-IR) in Centrally Obese Men Bayu Winata Putera; Cynthia Retna Sartika; Andi Wijaya
The Indonesian Biomedical Journal Vol 4, No 1 (2012)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v4i1.161

Abstract

BACKGROUND: Obesity is a major health problem in the world today. Obesity is closely associated with insulin resistance and type 2 diabetes. Epidemiological studies have shown that obese persons are in a state of insulin resistance, however, most of them do not progress to type 2 diabetes. This occurs because the beta cell function is still good enough for maintaining normal glucose level. Obestatin and visfatin are cytokines that are known to have a role in beta cell function. The aim of this study was to assess the relationship between visfatin and obestatin and Homeostasis Model Assessment of beta cell function (HOMA-β) and Homeostasis Model Assessment of insulin resistance (HOMA-IR).METHODS: This was a cross-sectional study involving 80 central obesity men with waist circumference >90 cm, age 30-65 years old. Visfatin and obestatin were measured by ELISA method. Beta pancreas cell dysfunction and insulin resistance were calculated by HOMA model.RESULTS: Our study showed a correlation between visfatin and HOMA-β (r=0.244 and p = 0.029) and visfatin with HOMA-IR (r=0.287 and p=0.001) and no correlation was found between obestatin with HOMA-β (r=0.010 and p=0.990) and obestatin with HOMA-IR (r=0.080 and p=0.480). We also found visfatin and obestatin concentrations were fluctuative depending on the measurements of the waist circumferences.CONCLUSIONS: High visfatin and low obestatin concentration were independently associated with increased beta pancreas cell dysfunction and insulin resistance.KEYWORDS: obesity. visfatin, obestatin, beta cell dysfunction (HOMA-β), insulin resistance (HOMA-IR)
Cost-Effectiveness Analysis of Pharmacotherapy for Hematemesis-Melena Treatment in Hospitalized Patients with Hepatic Cirrhosis Doddy de Queljoe; Amelia Lorensia; Liana Widharta; Sugiarto Widjaja
The Indonesian Biomedical Journal Vol 5, No 1 (2013)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v5i1.50

Abstract

BACKGROUND: Acute variceal haemorrhage is a complication of cirrhosis that can be life threatening. It is a pharmacist’s duty to ensure therapeutic and pharmaceutical care which is not only safe and effective for the patient but also is cost-effective in order to attain improvement of the patient’s quality of life. Therefore, pharmacoeconomic evaluation especially cost-effectiveness analysis (CEA), which compares costs and consequences of drug therapy, is needed. This study was aimed to evaluate the therapeutic cost-effectiveness of hematemesis-melena treatment in hepatic cirrhotic patients.METHODS: A total of 42 patients receiving vitamin K and vitamin K-transamin were studied retrospectively from patients’ medical records in 2 years and analyzed with cost-effectiveness grid and average cost-effectiveness ratio (ACER) based on Child-Turcotte-Pugh (CTP) Score.RESULTS: Cost-effectiveness grid was dominant for vitamin K in patients with CTP Score A. ACER analysis showed a lower score for vitamin K in all patients included CTP Score classification. There was no significant difference in duration of cessation of bleeding treatment in patients with vitamin K compared with vitamin K-transamin in patients with CTP Score A and B, while significant difference was found in patients with CTP Score C.CONCLUSION: Vitamin K appeared to be more cost effective as compared with vitamin K-transamin in all patients. The use of vitamin K had greater benefit than the combination with transamin in all patients and CTP Score classification, and thus should be considered as a primary therapy. Therefore, transamin addition as an alternative therapy for hepatic cirrhosis patients with hematemesis-melena should be considered.KEYWORDS: CEA, cost-effectiveness analysis, child-turcotte-pugh score, hepatic cirrhosis, hematemesismelena, vitamin K, transamin
A Comparative Study between Thoracic Epidural Anesthesia and General Anesthesia for Patients Who Underwent Modified Radical Mastectomy with Axillary Lymph Node Dissection in De La Salle University Medical Center Eva Oktavia
The Indonesian Biomedical Journal Vol 7, No 2 (2015)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v7i2.77

Abstract

BACKGROUND: To compare the recovery time and other related clinical outcomes among patients who underwent Modified Radical Mastectomy (MRM) with axillary lymph node dissection under Continuous Thoracic Epidural Anesthesia (CTEA) and General Endotracheal Tube Anesthesia (GETA).METHODS: A retrospective cross-sectional study with 70 patients who underwent MRM in De La Salle University Medical Centre (DLSUMC), categorized into GETA and CTEA group consisted of 35 patients each. Per oral premedications 15 mg midazolam, 40 mg omeprazole and 10 mg metoclopramide were given 1 hour prior to surgery. Intra-operative hypotension/hypertension, tachycardia/bradycardia status, length of Post-Anesthesia Care Unit (PACU) and hospital stay, and Post Operative Nausa and Vomiting (PONV) incidence were compared between 2 groups.RESULTS: Preoperatively, there were no significant differences between the groups in terms of subject characteristic. Intra-operatively, hypertension was more frequent in GETA group (28.6% vs. 0%), while hypotension was more frequent in the CTEA (80% vs. 57.1%). Tachycardia was more frequent in GETA group (46.6% vs. 0%), meanwhile bradycardia was more frequent in CTEA (40% vs. 17.1%). Postoperatively, the GETA group had shorter PACU stay than CTEA (230 mins vs. 267 mins), but CTEA group had a shorter time of hospital stay compared to GETA (58.1 hours vs. 67.7 hours). The incidence of PONV were comparable among the two groups (GETA 46.7% vs. CTEA 50%). Statistically there were no significant differences between the two groups in all of the above characteristics.CONCLUSION: CTEA technique has no effect on inducing hypertension and tachycardia, but hypotension and bradycardia may occur. Although GETA gives shorter PACU duration, CTEA gives shorter hospital stay. This gave impression that CTEA is an effective alternative technique to GETA in patients who underwent MRM with axillary dissection.KEYWORDS: modified radical mastectomy, general anesthesia, epidural anesthesia
Brown Adipose Tissue: A New Target for Antiobesity Therapy Anna Meiliana; Andi Wijaya
The Indonesian Biomedical Journal Vol 2, No 2 (2010)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v2i2.115

Abstract

BACKGROUND: Human fat consist of white and brown adipose tissue (WAT and BAT). Though most fat is energy-storing WAT, the thermogenic capacity of even small amounts of BAT makes it an attractive therapeutic target for inducing weight loss through energy expenditure.CONTENT: Over the past year, several independent research teams used a combination of positron-emission tomography and computed tomography (PET/CT) imaging, immunohistochemistry and gene and protein expression assays to prove conclusively that adult humans have functional BAT. BAT is important for thermogenesis and energy balance in small mammals and its induction in mice promotes energy expenditure, reduces adiposity and protects mice from diet-induced obesity. The thermogenic capacity of BAT is impressive. In humans, it has been estimated that as little as 50g of BAT could utilize up to 20% of basal caloric needs if maximally stimulated.SUMMARY: The obesity pandemic requires new and novel treatments. The past few years have witnessed multiple studies conclusively showing that adult humans have functional BAT, a tissue that has a tremendous capacity for obesity-reducing thermogenesis. Novel therapies targeting BAT thermogenesis may be available in the near future as therapeutic options for obesity and diabetes. Thermogenic ingredients may be considered as functional agents that could help in preventing a positive energy balance and obesity.KEYWORDS: brown adipose tissue, thermogenesis, energy expenditure, antiobesity therapy
Correlation of Neopterin and TNF-alpha with Asymmetric Dimethylarginine in Metabolic Syndrome Dedeh Yuniarty; Anwar Santoso; Mansyur Arif
The Indonesian Biomedical Journal Vol 3, No 3 (2011)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v3i3.151

Abstract

BACKGROUND: A large number of obesity in the community increases the incidence of Metabolic Syndrome (MetS) that can increase the risks of heart disease, diabetes, and stroke. One of the possible causes of stroke is atherosclerosis. Atherosclerosis is initiated by the incidence of inflammation and endothelial dysfuction. Atherosclerosis is involved in an ongoing inflammatory response. At the beginning of atherosclerosis, when the endothel become inflamed, it expresses adhesion molecules  that attract monocytes. The monocytes then migrate into the intima due to endothelial dysfunction. Activation of macrophage occurs in the process of inflammation as the earliest type of lesion of atherosclerosis. In this study, monocyte/macrophage activation is marked by Neopterin. In other process of atherosclerosis, vascular nitric oxide (NO) activity has a role as a potent endogenous vasodilator. In regulating the vascular tone, NO has a role to suppress vascular smooth muscle proliferation, inhibit platelet adhesion and aggregation, and interferes with the leukocyte-endothelial cell interaction. In MetS, hypercholesterolemia decreases NO activity. Asymmetric Dimethylarginine (ADMA) has been characterized as an endogenous, competitive inhibitor of NO synthase. In this study, the incidence of endothelial dysfunction is marked by ADMA. The aim of this study was to discover the role of Neopterin in MetS patients by evaluating the correlation between Neopterin and ADMA in MetS through tumor necrosis factor (TNF)-α or direct line.METHODS: The study was cross sectional on 64 males with MetS aged 30-65 years. The measurements of TNF-α concentrations was done, respectively.RESULTS: Neopterin concentration correlated with Log TNF-α concentration (r=0.311, p=0.012). There is no significant correlation between Neopterin and ADMA (r=0.012, p=0.930); ADMA and Log TNF-α (r=0.029, p=0.821).CONCLUSIONS: There is no significant correlation between Neopterin and ADMA through TNF-α or direct line.KEYWORDS: MetS, Neopterin, ADMA, NO, TNF-α
The Pharmacogenetics of Cytochrome P450 2C19 Enzymes - Effects on Clopidogrel and Proton Pump Inhibitors Yusmiati Yusmiati; Dewi Muliaty
The Indonesian Biomedical Journal Vol 6, No 1 (2014)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v6i1.41

Abstract

BACKGROUND: Cytochrome P450 (CYP) enzymes play important roles in human, including drug metabolism. CYP2 is the largest family of human CYP, with its sequence comprising almost one third of all CYP sequences, and responsible for the metabolism of approximately 2% of clinically administrated drugs. One of the most important enzymes in this family is the CYP2C19 enzyme. The CYP2C19 gene is polymorphic, and the variation is common especially in the Asian population.CONTENT: CYP2C19 is responsible for the metabolism of various drugs, including proton pump inhibitors (PPIs) such as omeprazole and lansoprazole, psychotropic drugs including diazepam and imipramine, anticonvulsants such as phenobarbital and mephenytoin. and the recently most studied the anti-platelet drug, clopidogrel, and many others. Drugs metabolized predominantly by this enzyme like clopidogrel and PPIs might be much affected by the genotype status of CYP2C19. Clopidogrel is a pro-drug requiring a group of enzymes to convert to its active form, particularly the CYP2C19. PPIs are metabolized to its inactive metabolites mainly by CYP2C19 in the liver. Some PPIs are inhibitor of CYP2C19 enzymes, and interaction of PPIs and clopidogrel has been widely studied.SUMMARY: The association of CYP2C19 genotypes with the plasma level of active clopidogrel and platelet reactivity in individual taking this drug is well-established. Although conflicting results still exist for the association of CYP2C19 genotypes to the clinical outcomes of clopidogrel therapy, this effect seems to be consistent in patients receiving clopidogrel for coronary stents. Due to the interaction of certain PPIs and clopidogrel, the use of PPIs other than omeprazole is recommended, especially for patients taking dual anti platelet therapy of clopidogrel and aspirin.KEYWORDS: pharmacogenetics, CYP2C19, proton pump inhibitors, clopidogrel
Cancer Immunotherapy: A Review Anna Meiliana; Nurrani Mustika Dewi; Andi Wijaya
The Indonesian Biomedical Journal Vol 8, No 1 (2016)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v8i1.189

Abstract

BACKGROUND: The goals of treating patients with cancer are to cure the disease, prolong survival, and improve quality of life. Immune cells in the tumor microenvironment have an important role in regulating tumor progression. Therefore, stimulating immune reactions to tumors can be an attractive therapeutic and prevention strategy.CONTENT: During immune surveillance, the host provides defense against foreign antigens, while ensuring it limits activation against self antigens. By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. The use of antibodies to block pathways inhibiting the endogenous immune response to cancer, known as checkpoint blockade therapy, has stirred up a great deal of excitement among scientists, physicians, and patients alike. Clinical trials evaluating the safety and efficacy of antibodies that block the T cell inhibitory molecules cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) have reported success in treating subsets of patients. Adoptive cell transfer (ACT) is a highly personalized cancer therapy that involve administration to the cancer-bearing host of immune cells with direct anticancer activity. In addition, the ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.SUMMARY: For cancer treatment, 2011 marked the beginning of a new era. The underlying basis of cancer immunotherapy is to activate a patient’s own T cells so that they can kill their tumors. Reports of amazing recoveries abound, where patients remain cancer-free many years after receiving the therapy. The idea of harnessing immune cells to fight cancer is not new, but only recently have scientists amassed enough clinical data to demonstrate what a game-changer cancer immunotherapy can be. This field is no stranger to obstacles, so the future looks very promising indeed.KEYWORDS: immune checkpoint, adoptive cell transfer, neoantigen, monoclonal antibody

Page 10 of 61 | Total Record : 601

 8   9   10   11   12 

Filter by Year

2009 2025


Reset
Filter By Issues
All Issue Vol 17, No 5 (2025) Vol 17, No 4 (2025) Vol 17, No 3 (2025) Vol 17, No 2 (2025) Vol 17, No 1 (2025) Vol 16, No 6 (2024) Vol 16, No 5 (2024) Vol 16, No 4 (2024) Vol 16, No 3 (2024) Vol 16, No 2 (2024) Vol 16, No 1 (2024) Vol 15, No 6 (2023) Vol 15, No 5 (2023) Vol 15, No 4 (2023) Vol 15, No 3 (2023) Vol 15, No 2 (2023) Vol 15, No 1 (2023) Vol 14, No 4 (2022) Vol 14, No 3 (2022) Vol 14, No 2 (2022) Vol 14, No 1 (2022) Vol 13, No 4 (2021) Vol 13, No 3 (2021) Vol 13, No 2 (2021) Vol 13, No 1 (2021) Vol 12, No 4 (2020) Vol 12, No 3 (2020) Vol 12, No 2 (2020) Vol 12, No 1 (2020) Vol 11, No 3 (2019) Vol 11, No 2 (2019) Vol 11, No 1 (2019) Vol 10, No 3 (2018) Vol 10, No 2 (2018) Vol 10, No 1 (2018) Vol 9, No 3 (2017) Vol 9, No 2 (2017) Vol 9, No 1 (2017) Vol 8, No 3 (2016) Vol 8, No 2 (2016) Vol 8, No 1 (2016) Vol 7, No 3 (2015) Vol 7, No 2 (2015) Vol 7, No 1 (2015) Vol 7, No 1 (2015) Vol 6, No 3 (2014) Vol 6, No 2 (2014) Vol 6, No 1 (2014) Vol 5, No 3 (2013) Vol 5, No 2 (2013) Vol 5, No 1 (2013) Vol 4, No 3 (2012) Vol 4, No 2 (2012) Vol 4, No 1 (2012) Vol 3, No 3 (2011) Vol 3, No 2 (2011) Vol 3, No 1 (2011) Vol 2, No 3 (2010) Vol 2, No 2 (2010) Vol 2, No 1 (2010) Vol 1, No 3 (2009) Vol 1, No 2 (2009) Vol 1, No 1 (2009) More Issue